CA3251002A1 - REMIBRUTINIB INTENDED FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVE - Google Patents
REMIBRUTINIB INTENDED FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVEInfo
- Publication number
- CA3251002A1 CA3251002A1 CA3251002A CA3251002A CA3251002A1 CA 3251002 A1 CA3251002 A1 CA 3251002A1 CA 3251002 A CA3251002 A CA 3251002A CA 3251002 A CA3251002 A CA 3251002A CA 3251002 A1 CA3251002 A1 CA 3251002A1
- Authority
- CA
- Canada
- Prior art keywords
- lou064
- treatment
- patient
- use according
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263314572P | 2022-02-28 | 2022-02-28 | |
| US63/314,572 | 2022-02-28 | ||
| US202263369016P | 2022-07-21 | 2022-07-21 | |
| US63/369,016 | 2022-07-21 | ||
| PCT/IB2023/051787 WO2023161887A1 (en) | 2022-02-28 | 2023-02-27 | Remibrutinib for use in the treatment of hidradenitis suppurativa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3251002A1 true CA3251002A1 (en) | 2023-08-31 |
Family
ID=85570288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3251002A Pending CA3251002A1 (en) | 2022-02-28 | 2023-02-27 | REMIBRUTINIB INTENDED FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVE |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250099465A1 (https=) |
| EP (1) | EP4486346A1 (https=) |
| JP (2) | JP7696006B2 (https=) |
| KR (1) | KR20240155278A (https=) |
| CN (1) | CN120617264A (https=) |
| AU (1) | AU2023225222A1 (https=) |
| CA (1) | CA3251002A1 (https=) |
| IL (1) | IL314205A (https=) |
| MX (1) | MX2024010392A (https=) |
| TW (1) | TW202342048A (https=) |
| WO (1) | WO2023161887A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250243170A1 (en) * | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| LT3380465T (lt) | 2015-11-26 | 2020-11-10 | Novartis Ag | Diamino piridino dariniai |
| JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| JP7007374B2 (ja) | 2016-09-23 | 2022-01-24 | ノバルティス アーゲー | 腱及び／又は靭帯損傷に使用するためのインダゾール化合物 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| MX2021014161A (es) | 2019-05-23 | 2022-01-04 | Novartis Ag | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. |
| HRP20251001T1 (hr) | 2019-05-23 | 2025-10-24 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije |
| BR112021023054A2 (pt) * | 2019-05-23 | 2022-03-29 | Novartis Ag | Formas cristalinas de um inibidor de btk |
| TW202142237A (zh) * | 2020-01-08 | 2021-11-16 | 美商普林斯匹亞生物製藥公司 | 包含2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4,4-二甲基戊-2-烯腈之局部醫藥組成物 |
| TWI905371B (zh) | 2021-01-26 | 2025-11-21 | 瑞士商諾華公司 | 藥物組成物 |
-
2023
- 2023-02-24 TW TW112107010A patent/TW202342048A/zh unknown
- 2023-02-27 IL IL314205A patent/IL314205A/en unknown
- 2023-02-27 US US18/729,542 patent/US20250099465A1/en active Pending
- 2023-02-27 KR KR1020247031567A patent/KR20240155278A/ko active Pending
- 2023-02-27 EP EP23710457.5A patent/EP4486346A1/en active Pending
- 2023-02-27 AU AU2023225222A patent/AU2023225222A1/en active Pending
- 2023-02-27 WO PCT/IB2023/051787 patent/WO2023161887A1/en not_active Ceased
- 2023-02-27 CA CA3251002A patent/CA3251002A1/en active Pending
- 2023-02-27 JP JP2023553381A patent/JP7696006B2/ja active Active
- 2023-02-27 MX MX2024010392A patent/MX2024010392A/es unknown
- 2023-02-27 CN CN202511059211.7A patent/CN120617264A/zh active Pending
-
2025
- 2025-06-09 JP JP2025095960A patent/JP2025134747A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486346A1 (en) | 2025-01-08 |
| JP2024511938A (ja) | 2024-03-18 |
| JP7696006B2 (ja) | 2025-06-19 |
| WO2023161887A1 (en) | 2023-08-31 |
| IL314205A (en) | 2024-09-01 |
| TW202342048A (zh) | 2023-11-01 |
| MX2024010392A (es) | 2024-09-06 |
| US20250099465A1 (en) | 2025-03-27 |
| KR20240155278A (ko) | 2024-10-28 |
| AU2023225222A1 (en) | 2024-07-25 |
| JP2025134747A (ja) | 2025-09-17 |
| CN120617264A (zh) | 2025-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2724339C2 (ru) | Сенекривирок для лечения фиброза | |
| RU2748549C2 (ru) | Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата | |
| CN106999593A (zh) | 用于纤维化治疗的赛尼克韦罗组合疗法 | |
| JP2022044767A (ja) | 癌を処置する方法 | |
| CN117205312A (zh) | 治疗癌症的卡博替尼与阿特珠单抗组合 | |
| JP2026048721A (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| AU2020280272B2 (en) | Methods of treating Chronic Spontaneous Urticaria using a Bruton's tyrosine kinase inhibitor | |
| AU2022245186A1 (en) | Treatment of hidradenitis suppurativa with orismilast | |
| JP2010508277A (ja) | 癌を検出および抑制するための方法 | |
| JP2025134747A (ja) | 化膿性汗腺炎の治療における使用のためのレミブルチニブ | |
| AU2017227515B2 (en) | Imatinib for use in the treatment of stroke | |
| KR20220088830A (ko) | 비뇨기계암의 치료 방법 | |
| CN107405403A (zh) | 用于治疗纤维化的塞尼克韦罗 | |
| AU2018209807B2 (en) | Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy | |
| JP7594124B2 (ja) | Ｌｏｕ０６４を使用した治療の方法 | |
| EA051701B1 (ru) | Ремибрутиниб для применения в лечении гнойного гидраденита | |
| CN118742308A (zh) | 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼 | |
| CN117479936A (zh) | 用奥瑞司特治疗化脓性汗腺炎 | |
| TW202539668A (zh) | 使用索樂匹尼布處置免疫性血小板減少症的方法 | |
| EA051816B1 (ru) | Способы лечения с применением lou064 | |
| JP2021511380A (ja) | 腫瘍増殖を抑制するためのミナプリンの使用 | |
| El Rakaawi et al. | THU0397 Efficacy of pamidronate in children with osteogenesis imperfecta: An open prospective study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240806 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250107 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250107 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250121 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250121 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250214 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251216 |